

1     **Longitudinal analysis of genetic and environmental interplay in**  
2             **human metabolic profiles and the implication for metabolic**  
3                     **health**

4     Jing Wang<sup>1#</sup>, Alberto Zenere<sup>1#</sup>, Xingyue Wang<sup>1#</sup>, Göran Bergström<sup>2</sup>, Fredrik Edfors<sup>3</sup>, Mathias Uhlén<sup>3</sup>,  
5     Wen Zhong<sup>1\*</sup>

6  
7     <sup>1</sup> Science for Life Laboratory, Department of Biomedical and Clinical Sciences (BKV), Linköping  
8     University, Linköping, Sweden.

9     <sup>2</sup> Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg,  
10     and Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

11     <sup>3</sup> Department of Protein Science, KTH - Royal Institute of Technology, Stockholm, Sweden

12  
13  
14     \* To whom correspondence should be addressed: Wen Zhong

15     Address: Department of Biomedical and Clinical Sciences (BKV), Linköping University, SE-581 83,  
16     Linköping

17     Email: wen.zhong@liu.se

18     Phone: + 46 729419808

19     # Equal contribution; these authors share first authorship.

20

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 21 **Abstract**

### 22 **Background**

23 Understanding how genetics and environmental factors shape human metabolic profiles is crucial for  
24 advancing metabolic health. Variability in metabolic profiles, influenced by genetic makeup, lifestyle,  
25 and environmental exposures, plays a critical role in disease susceptibility and progression.

### 26 **Methods**

27 We conducted a two-year longitudinal study involving 101 clinically healthy individuals aged 50 to 65,  
28 integrating genomics, metabolomics, lipidomics, proteomics, clinical measurements, and lifestyle  
29 questionnaire data from repeat sampling. We evaluated the influence of both external and internal  
30 factors, including genetic predispositions, lifestyle factors, and physiological conditions, on individual  
31 metabolic profiles. Additionally, we developed an integrative metabolite-protein network to analyze  
32 protein-metabolite associations under both genetic and environmental regulations.

### 33 **Results**

34 Our findings highlighted the significant role of genetics in determining metabolic variability, identifying  
35 22 plasma metabolites as genetically predetermined. Environmental factors such as seasonal variation,  
36 weight management, smoking, and stress also significantly influenced metabolite levels. The integrative  
37 metabolite-protein network comprised 5,649 significant protein-metabolite pairs and identified 87  
38 causal metabolite-protein associations under genetic regulation, validated by showing a high replication  
39 rate in an independent cohort. This network revealed stable and unique protein-metabolite profiles for  
40 each individual, emphasizing metabolic individuality. Notably, our results demonstrated the importance  
41 of plasma proteins in capturing individualized metabolic variabilities. Key proteins representing  
42 individual metabolic profiles were identified and validated in the UK Biobank, showing great potential  
43 for predicting metabolic diseases and metabolic risk assessment.

### 44 **Conclusions**

45 Our study provides longitudinal insights into how genetic and environmental factors shape human  
46 metabolic profiles, revealing unique and stable individual metabolic profiles. Plasma proteins emerged

47 as key indicators for capturing the variability in human metabolism and assessing metabolic risks. These  
48 findings offer valuable tools for personalized medicine and the development of diagnostics for  
49 metabolic diseases.

## 50 **Keywords**

51 Human metabolism, genetics, proteomics, metabolomics, lifestyle, environment, metabolic risk

52

## 53 **Background**

54 The human metabolome is dynamic, and the variability in human metabolic profiles across individuals  
55 is shaped by each person's unique genetic makeup, lifestyle, and environmental exposures<sup>1,2</sup>. These  
56 factors play critical roles in disease susceptibility and progression, including obesity, diabetes,  
57 hypertension, cardiovascular disease and other metabolic abnormalities<sup>3-6</sup>. Despite significant  
58 advancements in metabolomics, the determinants of individual metabolic variability remain  
59 incompletely understood. Twin studies have revealed a broad range of heritability for metabolite levels  
60 in human plasma<sup>7,8</sup>, and genome-wide association studies (GWAS) have identified numerous genetic  
61 variants influencing metabolite levels (mQTL, metabolite quantitative trait loci)<sup>9-13</sup>. This demonstrates  
62 the important role of genetics in human metabolism for the understanding of individual metabolic  
63 diversity. Beyond genetics, human metabolic profiles are also influenced by various factors such as  
64 obesity<sup>14-16</sup>, lifestyle<sup>17</sup>, diet<sup>2,18,19</sup>, microbiome<sup>2,18,19</sup>, medications<sup>20</sup>, and other environmental exposures.  
65 For instance, by analyzing fasting plasma profiles of 1,183 metabolites in 1,679 samples from 1,368  
66 individuals, Chen et al.<sup>21</sup> found that diet, genetics and the gut microbiome could explain 9.3%, 3.3%  
67 and 12.8%, respectively, of the inter-individual variations in plasma metabolomics.

68 However, these GWAS and association studies often overlook the temporal dynamics and  
69 environmental interactions that continuously influence the metabolome. Seasonal variations, for  
70 instance, introduce another layer of complexity in metabolite levels<sup>22-24</sup>, reflecting changes in  
71 environmental conditions, dietary habits, physical activity, and other lifestyle factors<sup>25,26</sup>. The  
72 heterogeneity in metabolite levels among individuals further underscores their multifaceted roles in

73 various biological processes<sup>27,28</sup>. To accurately contextualize this variability in human metabolism,  
74 incorporating longitudinal molecular data from the same individuals is crucial. This approach allows  
75 for the monitoring of dynamics in metabolite levels in response to external influences and internal  
76 physiological changes, providing a more comprehensive understanding of individual metabolite  
77 variability<sup>5,29,30</sup>. In addition, longitudinal data can reveal temporal metabolic regulation patterns that are  
78 not apparent in cross-sectional studies<sup>31</sup>, offering deeper insights into the dynamic interplay between  
79 genetic predispositions and environmental factors and advancing precision medicine for metabolic  
80 health.

81 Here, we conducted a detailed longitudinal multi-omics analysis involving 101 individuals aged 50-65  
82 over two years to explore the dynamics and individual differences in metabolic profiles. The influences  
83 of genetic predispositions, lifestyle factors, and physiological conditions on individual metabolic  
84 profiles have been investigated. Additionally, we established an integrative metabolite-protein network  
85 and identified key proteins and metabolites associated with human metabolic risk. This work contributes  
86 to a more comprehensive understanding of individual metabolite variability and advances our  
87 knowledge in more personalized approaches to monitoring metabolic health.

## 88 **Methods**

### 89 **The wellness profiling study**

90 The Swedish SciLifeLab SCAPIS Wellness Profiling (S3WP) study is an observational study aimed at  
91 gathering longitudinal clinical and molecular data from a community-based cohort. This study derived  
92 from the Swedish CARdioPulmonary bioImage Study (SCAPIS), which is a prospective observational  
93 study with 30,154 individuals aged 50 to 65 years at enrollment, randomly selected from the general  
94 Swedish population between 2015 and 2018<sup>32</sup>. In SCAPIS, no exclusion criteria are applied except the  
95 inability to understand written and spoken Swedish for informed consent. In the S3WP study, we  
96 enrolled 101 healthy individuals with the following exclusion criteria: (1) previously received health  
97 care for myocardial infarction, stroke, peripheral artery disease, or diabetes, (2) presence of any  
98 clinically significant disease which, in the opinion of the investigator, may interfere with the results or

99 the subject's ability to participate in the study, (3) any major surgical procedure or trauma within 4  
100 weeks of the first study visit, or (4) medication for hypertension or hyperlipidemia. Before enrolling in  
101 the S3WP study, all subjects had been extensively assessed by SCAPIS<sup>32</sup>. Throughout the duration of  
102 the S3WP study, follow-up visits are conducted every third month ( $\pm 2$  weeks) in the first year and  
103 approximately a 6-month interval in the second year. All subjects were fasting overnight (at least 8 h)  
104 before the visits. Lifestyle questionnaires, anthropometric measurements, clinical measurements, and  
105 plasma proteome profiling, metabolome profiling and lipidome profiling were examined at each of the  
106 follow-up visit. Whole genome sequencing data were detected at the baseline (**Fig. 1a, Additional file**  
107 **2: Table S1**). The study has been approved by the Ethical Review Board of Göteborg, Sweden  
108 (registration number 407-15), and all participants provided written informed consent. The study  
109 protocol adheres to the ethical guidelines outlined in the 1975 Declaration of Helsinki.

#### 110 **Self-reported questionnaires**

111 Self-reported questionnaires, comprised 140 questions, were used to gather detailed information  
112 covering health, family history, medication, occupational and environmental exposure, lifestyle,  
113 psychosocial well-being, socioeconomic status, and other social determinants. These questionnaires had  
114 been administered in the SCAPIS trial. During each visit in the S3WP program, a selection of these  
115 questions was repeated to update the information from the initial SCAPIS questionnaire. Additionally,  
116 participants were asked about any changes in lifestyle factors between visits, such as infections, disease,  
117 medication, perceived health, and exercise level.

#### 118 **Anthropometric and clinical measurements**

119 Height was measured to the nearest centimeter without shoes, with participants wearing indoor clothing.  
120 Weight was recorded on a calibrated digital scale under the same conditions. BMI was calculated by  
121 dividing weight (kg) by the square of height (m). Waist circumference was measured midway between  
122 the iliac crest and the lowest rib margin in the left and right mid-axillary lines. Hip circumference was  
123 measured at the widest part of the buttocks. Bioimpedance was assessed using the Tanita MC-780MA  
124 following the manufacturer's instructions. Systolic and diastolic blood pressure were measured in the  
125 supine position after a 5-minute rest using the Omron P10 automatic device. Blood pressure was initially

126 measured in both arms during the first visit, and subsequently in the arm that showed the highest reading.  
127 Clinical chemistry and hematology assessments included capillary glucose (Hemocue), plasma glucose,  
128 HbA1c, triglycerides, total cholesterol, LDL, HDL, ApoA1, ApoB, ApoA1/B ratio, creatinine, high-  
129 sensitive C-reactive protein (hsCRP), ALAT, GGT, urate, cystatin C, vitamin D, TNT, NTproBNP,  
130 hemoglobin, and blood cell count. The complete list of the clinical variables can be found in **Additional**  
131 **file 2: Table S1**.

### 132 **Whole genome sequencing**

133 The whole genome-sequencing procedure has been detailed previously by Zhong et al. <sup>33,34</sup>. Briefly,  
134 Genomic DNA was sequenced to average 30X coverage on the HiSeq X system (Illumina, paired-end  
135  $2 \times 150$  bp). The alignment was performed using BWA-mem using GRCh38.p7 as reference genome.  
136 Single-nucleotide and insertion/deletion variants were called following the GATK pipeline  
137 (<https://software.broadinstitute.org/gatk/best-practices>; GATK v3.6). BCFtools<sup>35</sup> and PLINK 2.0<sup>36</sup> were  
138 used to perform quality control (QC). The exclusion criteria included: (1) removing variants which did  
139 not receive the “PASS” tag from GATK; (2) removing variants with minQUAL <30; (3) removing  
140 variants/samples that with a genotyping rate < 0.05; (5) removing variants with a low minor allele  
141 frequency (MAF) (<5%); (6) removing variants that failed the Hardy–Weinberg equilibrium (HWE)  
142 test ( $P < 1 \times 10^{-6}$ ). In total, 6,691,390 high-quality variants were identified in all samples. Functional  
143 annotation of variants was performed using Ensembl Variant Effect Predictor (VEP) v111<sup>37</sup>.

### 144 **Plasma metabolomics and lipidomics profiling**

145 Plasma metabolites and lipids profiling were obtained by gas chromatography-mass spectrometry (GC-  
146 MS) and liquid chromatography-mass spectrometry (LC-MS)<sup>29</sup>. Briefly, the metabolites were extracted  
147 by using Agilent 1290 Infinity UHPLC-system (reverse phase chromatography) combined with an  
148 Agilent 6550 Q-TOF mass spectrometer equipped with an electrospray Jetstream ion source operating  
149 in positive and negative ion mode. The  $m/z$  range was 70-1700, and data were collected in centroid  
150 mode with an acquisition rate of 4 scans/s. The mass spectrometry files were processed using Profinder  
151 B.08.01 (Agilent Technologies Inc., Santa Clara, CA, USA). Peak detection was performed using mass  
152 feature extraction. The lipids were extracted following a modified Folch protocol <sup>38</sup>. The data were

153 processed using Batch Targeted Feature Extraction algorithm within MassHunter™ ProFinder version  
154 B.08.00 (Agilent Technologies Inc., Santa Clara, CA, USA). In-house databases with exact mass and  
155 experimental retention times of lipids were used for identification. The detailed method can be found  
156 in Tebani et al.<sup>29</sup>. In total, 456 metabolites were identified in 101 subjects and 173 lipids were measured  
157 in 50 subjects.

158 All metabolite concentrations were log<sub>2</sub>-transformed to approximate a normal distribution. Metabolites  
159 with any of the following conditions have been removed: (1) metabolites that failed detection in at least  
160 30% of samples; (2) the ratio of maximum and minimum interquartile range (IQR) of metabolite  
161 concentrations across four visits > 2; (3) duplicated metabolites. In addition, 5 subjects were removed  
162 because they participated in < 4 follow-ups. The filtering process retained a total of 527 unique  
163 metabolites for 96 subjects (357 metabolites based on 96 subjects and 170 lipids based on 50 subjects)  
164 for the downstream analysis of the study.

165 Metabolite annotation was performed using resources from the Human Metabolomics Database  
166 (HMDB) (version 5.0)<sup>39</sup> and relevant literature<sup>4,7-10</sup>. A total of 527 metabolites were categorized into  
167 9 main classes and 63 subclasses. Additionally, 11 lipid subclasses were further subdivided into 23  
168 secondary lipid subclasses, resulting in the creation of 75 custom terms. These customized terms, along  
169 with metabolic pathways curated in the Small Molecule Pathway Database (SMPDB), were used for  
170 the enrichment analysis of metabolites. The complete list of the customized terms can be found in  
171 **Additional file 2: Table S3.**

## 172 **Plasma protein profiling**

173 We used a multiplex proximity extension assay (Olink Bioscience, Uppsala Sweden) to measure the  
174 relative concentrations of 794 plasma proteins in eleven Olink panels. To minimize inter-run and intra-  
175 run variation, the samples were randomized across plates and normalized using both an internal control  
176 (extension control) and an inter-plate control; then a pre-determined correction factor was applied to  
177 transform the data. The pre-processed data were provided in the arbitrary unit Normalized Protein  
178 eXpression (NPX) on a log<sub>2</sub> scale. QC procedures were performed at both sample and protein level.  
179 Briefly, samples were flagged (did not pass QC) if the incubation control deviated more than a pre-

180 determined value ( $\pm 0.3$ ) from the median value of all samples on the plate ([www.olink.com](http://www.olink.com)). To  
181 reduce the batch effect between samples run at different times, bridging reference samples from  
182 different visits were also run on plates from the different batches. Reference sample normalization based  
183 on bridging samples was conducted to minimize technical variation between batches ([www.olink.com](http://www.olink.com)).  
184 After QC, a total of 794 unique proteins for 90 subjects and 6 visits (540 samples) were retained for  
185 analysis. The detailed information about plasma protein profiling can be found in previous papers<sup>34,33</sup>.  
186 Proteins were annotated according to their molecular function, following the Human Protein Atlas v23  
187 (<https://www.proteinatlas.org/>).

### 188 **Co-expression analysis of plasma metabolites**

189 Before performing co-expression analysis, metabolomics and lipidomics data for 527 metabolites were  
190 scaled to zero mean and unit variance. UMAP was applied as an unsupervised clustering modeling  
191 method for dimensionality reduction, providing an overview of clustering patterns among samples with  
192 similar data profiles. The K Nearest Neighbour Search (KNN) algorithm was implemented to calculate  
193 the adjacency matrix using the ‘nn2’ function from the R package RANN v2.6.1<sup>40</sup>, setting the maximum  
194 number of nearest neighbors to 20. To calculate the number of shared nearest neighbors (SNN), we  
195 employed the ‘sNN’ function from the R package dbscan v1.1.11<sup>41</sup>, considering 5 neighbors for the  
196 calculation. R package igraph v1.5.0<sup>42</sup> was used to build the adjacency matrix based on the nearest  
197 neighbor results for each metabolite and to identify communities using the ‘cluster\_louvain’ function.  
198 In total, 19 clusters were identified from the initial clustering. The mean scaled abundance of  
199 metabolites within each of these 19 clusters was then used for a second step of hierarchical clustering.  
200 Euclidean distances between the 19 clusters were computed, and similarities were assessed using the  
201 ward.D2 method. The hierarchical clustering dendrogram was subsequently divided into 8 distinct  
202 groups, resulting in the identification of 8 unique metabolite clusters (**Additional file 2: Table S2**).

### 203 **Seasonal variation analysis**

204 The seasonal patterns of both metabolites and proteins were analyzed by calculating the amplitude of  
205 their temporal expressions. The amplitude was defined as the square root of the sum of the squares of  
206 the coefficients of the sine and cosine terms of sampling month from the fitted seasonal model:



207 
$$\text{molecular abundance} \sim \sin\left(\frac{2\pi \cdot \text{month}}{12}\right) + \cos\left(\frac{2\pi \cdot \text{month}}{12}\right) + \text{Sex} + \text{BMI} + \text{Age} + (1|\text{individual}) \quad (1)$$

208 To identify temporally co-expressed metabolites and proteins, Euclidean distances were calculated for  
209 those showing significant results associated with sampling month (FDR-adjusted  $P < 0.05$ ) based on  
210 their scaled mean intensity at each month. Clustering analysis was then performed using the ‘ward.D2’  
211 method in the ‘hclust’ function from the R ‘stats’ package. The resulting hierarchical clustering tree was  
212 divided into distinct seasonal groups, revealing unique patterns of seasonal variation (**Additional file**  
213 **2: Table S5 and Additional file 2: Table S8**).

#### 214 **Genome-wide association analysis of plasma metabolites**

215 For each plasma metabolite, we calculated the coefficients of metabolite intensity for each subject using  
216 a linear regression model, with visit included as a covariate. These coefficients served as adjusted  
217 metabolite levels for subsequent GWAS analysis. GWAS was conducted using the PLINK v2.0<sup>36</sup>,  
218 employing a linear regression model that included body mass index (BMI), sex, and age as covariates.  
219 To identify independent mQTLs, linkage disequilibrium (LD)  $r^2 > 0.1$  with window size 1 Mb was first  
220 used to exclude the correlated variants. Given the high correlation among metabolites, we utilized an  
221 eigendecomposition method to estimate the effective number of independent metabolites<sup>4</sup>. Out of the  
222 527 metabolites, the estimated number of independent metabolites was 23, and this number was used  
223 to calculate the Bonferroni threshold for multiple hypothesis testing ( $5 \times 10^{-8} / 23 = 2.17 \times 10^{-9}$ ). For  
224 metabolites associated with multiple mQTLs, conditional analysis was performed by re-calculating  
225 genetic associations using the lead single-nucleotide polymorphism (SNP) as a covariate. Only  
226 associations with a conditional  $P$ -value  $< 0.01$  were considered to be independent mQTLs. A total of 66  
227 significant associations between genetic variants and individual blood metabolite concentrations were  
228 identified. Among them, 19 independent metabolite quantitative trait loci (mQTLs) (Linkage  
229 Disequilibrium, LD,  $r^2 < 0.1$ , conditional  $P < 0.01$ ) involving 22 metabolites were identified  
230 (**Additional file 2: Table S11**).

## 231 **Meta-analysis of plasma metabolite GWAS**

232 For the meta-analysis of plasma metabolite GWAS, we included six out of 22 identified genetic-related  
233 metabolites with available published GWAS summary results. The GWAS summary data from  
234 published studies<sup>4,7</sup> was retrieved via the GWAS Catalog ([www.ebi.ac.uk/gwas/](http://www.ebi.ac.uk/gwas/), accession date:  
235 2023.10), including 3 cohorts: Cooperative Health Research in the Region of Augsburg (KORA, N =  
236 1768), TwinsUK (N = 1052) and Canadian Longitudinal Study of Aging (CLSA, N = 8,299). All these  
237 three cohorts comprised relatively healthy European individuals. To ensure consistency across datasets,  
238 we used LiftOver<sup>43</sup> to convert the genome coordinates to the GRCh38 reference genome. The meta-  
239 analysis was performed on these three cohorts along with our study, involving a total of 5.8 million  
240 SNPs, using an inverse-variance fixed-effect model using GWAMA v2.2.2<sup>44</sup>. The genome-wide  
241 significance threshold for the meta-analysis was set at  $P < 8.33 \times 10^{-9}$ , accounting for multiple testing  
242 correction ( $5 \times 10^{-8} / 6$ ).

## 243 **Experimental validation**

244 ACADS short interfering RNA (siRNA) and negative control siRNA were transfected into 293T cells.  
245 Following a 48-hour incubation period, the cells were collected and divided into two equal portions.  
246 One portion was lysed and quantified using the Bicinchoninic Acid (BCA) Protein Assay Kit. Equal  
247 amounts of protein lysate from each sample were used for immunoblotting to assess the expression  
248 levels of the ACADS protein. The immunoblotting results were analyzed to determine the efficacy of  
249 ACADS knockdown. The remaining portion of the cells was processed for metabolite analysis.  
250 Specifically, the relative content of butyrylcarnitine was measured using a liquid chromatography-  
251 quadrupole time-of-flight mass spectrometer (LC-QTOF MS, Agilent #1290-6546). The mass  
252 spectrometer was equipped with Agilent Jet-stream source operating in negative and positive ion mode  
253 with source parameters set as follow: Nebulizer gas, 45psi; Sheath gas temperature, 325 °C; Sheath gas  
254 flow, 10L/min; Dry gas temperature, 280 °C; Dry gas flow, 8L/min; Capillary voltage, 3500v for two  
255 ion modes and nozzle voltage, 500v for positive and 1000v for negative mode. The QTOF scan  
256 parameters were set as follows: Scan speed, 2 scan/s. Separation of metabolites was achieved in a Waters  
257 ACQUITY UPLC BEH Amide column(2.1 mm × 100 mm × 1.7 μm) and guard column (2.1 mm × 5

258 mm × 1.7 μm). Agilent Masshunter profiler 10.0 was used to extract its characteristic m/z 232.1547  
259 ion from the total ion chromatogram. Butyrylcarnitine was quantified by peak area. Data analysis was  
260 conducted using Agilent MassHunter profiler 10.0 software. The detailed experimental setup are  
261 provided in **Supplementary Information**.

### 262 **Protein-metabolite association analysis, Mendelian randomization, and network analysis**

263 Linear mixed modeling (LMM) was conducted to identify associations between 527 metabolites and  
264 794 proteins, with sex, age, and BMI as fixed effects, and subject and visit as random effects. The  
265 analysis was performed using the ‘lmerTest’ package<sup>45</sup>, and the Kenward-Roger approximation was  
266 applied to calculate *P*-value using the R package ‘pbkrtest’ v0.5.2<sup>46</sup>. In addition, one-sample MR  
267 analysis was performed to test the causal relationships between protein-metabolite pairs identified  
268 through LMM (FDR-adjusted *P* < 0.05). This analysis utilized instrumental variable (IV) regression by  
269 two-stage least squares (2SLS) using the ‘ivreg’ function from the R package AER 1.2-10<sup>47</sup>, which is  
270 based on Sex, age and BMI were included in the regression models as covariates, while the independent  
271 pQTLs (genome-wide significance, *P* < 5×10<sup>-8</sup>) associated with the protein were used as IVs. SNP  
272 would be removed from the IVs if it had more than 5 association across the proteins<sup>13</sup>. The full list of  
273 IVs was provided in **Additional file 2: Table S15**.

274 The protein-metabolite association network was constructed by combining both the LMM and MR  
275 results. Betweenness centrality score for each node in the network was calculated using the function  
276 ‘betweenness’ from the package ‘igraph’ v1.5.0<sup>42</sup>. Proteins and metabolites with a score > MAD above  
277 the respective median were classified as Tier 2, while proteins and metabolites with a score >2×MAD  
278 the median were categorized as Tier 1. All significant (FDR-adjusted *P* < 0.05) protein-metabolite pairs  
279 identified from the LMM were used to perform a UMAP clustering based on samples without missing  
280 values.

### 281 **Metabolic risk stratification of participants in the study**

282 To evaluate the metabolic risk levels of participants at various study visits, five classical metabolic risk  
283 indicators were utilized: body mass index (BMI), high-density lipoprotein (HDL), systolic blood  
284 pressure (SBP), fasting glucose (Gluc), and triglycerides (TG). Each measurement was normalized by

285 adjusting for sex-specific effects and then dividing by the standard deviation across all samples. K-  
286 means clustering was performed to stratify the samples into two groups (high risk and low risk) using  
287 the function ‘kmeans’ from the R package ‘stats’<sup>48</sup>. Additionally, other clinical biochemical markers,  
288 including alanine aminotransferase (ALAT), gamma-glutamyltransferase (GGT), urate, troponin T  
289 (TNT), and white blood cells (WBC), were normalized in a same way. These markers were then used  
290 to test for differential expression levels between the two stratified metabolic risk groups.

### 291 **Individuals with metabolic diseases in the UK Biobank**

292 The UK Biobank is a large-scale biomedical database and research resource that includes genetic,  
293 lifestyle, and health information from half a million UK participants aged 40-69 at baseline<sup>49,50</sup>.  
294 Participants were enrolled from 2006 to 2010 in 22 recruitment centers across the UK, with follow-up  
295 data continuously collected. Proteomic profiling was conducted on blood plasma samples collected  
296 during baseline recruitment from a randomized subset of UK Biobank participants. For this study, we  
297 focused on Normalized Protein Expression (NPX) data for Tier 1 proteins and extracted metabolic  
298 disease diagnoses information (field ID: 41202, ICD 10: E10, E11, E66, E03, E05, E78, M10, E88).  
299 Participants with available proteome data for Tier 1 proteins were selected. To validate the predictive  
300 power of Tier 1 proteins for various metabolic diseases, we focused on diseases with sufficient case  
301 numbers for proteome analysis. Only data from participants diagnosed before baseline recruitment were  
302 included, and individuals with multiple diagnoses were excluded. This resulted in the inclusion of type  
303 2 diabetes (N = 144), obesity (N = 25), hyperthyroidism (N = 21), and gout (N = 27) for predictive  
304 analysis.

305 For robust statistical analysis, NPX values were rank-inverse normal-transformed. Remaining missing  
306 values were imputed using the average value calculated across all individuals. Ultimately, the dataset  
307 comprised 242 participants in the metabolic disease group and 5,511 in the healthy group.

### 308 **Identification of individuals who develop obesity in the UK Biobank**

309 To identify individuals at risk of developing obesity in the future, we utilized BMI records (field  
310 ID:21001) from the UK Biobank, which included baseline recruitment data collected between 2006 and

311 2010 and three follow-up visits in 2012-2013, 2014+, and 2019+. Participants with a baseline BMI  
312 lower than 25 kg/m<sup>2</sup> were included in the analysis. These individuals were further stratified into two  
313 groups: the ‘future obese’ group, consisting of individuals who recorded a BMI higher than 30 kg/m<sup>2</sup> in  
314 at least one of the three follow-up visits, and the ‘control’ group, comprising individuals who maintained  
315 a BMI lower than 30 kg/m<sup>2</sup> across all subsequent visits. To ensure data quality and relevance, we filtered  
316 the samples based on the availability of proteome data for Tier 1 proteins. This filtering process resulted  
317 in the classification of fifteen individuals into the ‘future obesity’ group and 3,185 individuals into the  
318 control group.

### 319 **Machine learning for predictive tasks**

320 To develop and validate prediction models, the samples were randomly split into training and validation  
321 datasets using a 7:3 ratio. For analyses performed on the S3WP data, samples from the same individuals  
322 were kept together in either the training or validation group. For the UK Biobank data, balanced datasets  
323 were constructed by randomly selecting an equal number of control samples for predicting metabolic  
324 diseases. All data were scaled before the prediction analysis. The prediction models were built using  
325 the XGBClassifier from the Python library xgboost v2.0.3<sup>51</sup> with “binary:logistic” used as the objective.  
326 To address class imbalance, the subsample parameter was set to 0.5, and the scale\_pos\_weight  
327 parameter was adjusted to the ratio of negative and positive samples. The model training and validation  
328 procedure was repeated 100 times, each time with a different random split of the data, to account for  
329 stochastic variability in the selection of training and validation data. Receiver operating characteristic  
330 (ROC) curves were generated and visualized using the R package ‘verification’ v1.42<sup>52</sup>.

### 331 **Statistical analysis and visualization**

332 Uniform Manifold Approximation and Projection (UMAP) was performed by using the R package  
333 umap<sup>53</sup>. Canonical correspondence analysis (CCA) was performed including lifestyle factors,  
334 anthropometric and clinical measurements, and visit as constraining variables using the R package  
335 vegan v2.6.4<sup>54</sup>. The association between each variable and CCA1 and CCA2 was quantified by the  
336 estimated coefficient obtained from univariate linear regression. The mixed model expressed by  
337 equation (1) was used to determine the associations between sex, BMI, age, seasonality and metabolite

338 abundance, with metabolite abundance as response, sex, BMI, age, and month of sampling as fixed  
339 effects and subject as random effect. All of mixed model analyses were performed using the lmerTest  
340 package<sup>45</sup> and Kenward-Roger approximation was applied to calculate *P*-value using the R package  
341 pbkrtest v0.5.2<sup>46</sup>. Variance analysis of metabolites and UMAP components was conducted using a linear  
342 regression model including significantly associated mQTLs (and pQTLs for UMAP components),  
343 clinical measurements, lifestyle parameters, sex, age, and visit as variables. The fraction of explained  
344 variability was measured as the Sum of Squares Explained (SSE) and *p*-value was determined using  
345 Analysis of Variance (ANOVA) by the built-in R function aov. Pearson correlation was used to estimate  
346 the correlation between metabolites and proteins. Kruskal-Wallis test and *t*-test were used to compare  
347 differences in the levels of metabolites or proteins between groups. Fisher's exact test was used for  
348 enrichment analysis of metabolites. FDR was calculated for multiple testing correction by using the  
349 function p.adjust, selecting the Benjamini-Hochberg method. FDR-adjusted *P* <0.05 was considered  
350 significant in the analysis.

351 The Sankey plot was generated using the function sankeyNetwork of R package networkD3 v0.4<sup>55</sup>. The  
352 heatmap was generated using the R package pheatmap v1.0.12<sup>56</sup>. Networks were created using the R  
353 package igraph v1.5.0<sup>42</sup>. Chord diagrams were generated using the R packages circlize<sup>57</sup>. Spider plots  
354 were generated using the package ggradar v0.2<sup>84</sup>. The package ggalluvial v0.12.5<sup>58</sup> was used to show  
355 the group of the samples from the same individual across the six visits. All the other visualizations were  
356 performed using the ggplot2<sup>59</sup> R package. All of the data analysis and visualization was performed using  
357 the R project<sup>60</sup>.

## 358 **Results**

### 359 **Longitudinal analysis of human metabolic profiles in a wellness study**

360 To systematically investigate the human metabolic profiles over time, we performed a comprehensive  
361 integrative multi-omics analysis of 101 participants in the Swedish SciLifeLab SCAPIS Wellness  
362 Profiling (S3WP) program over two years<sup>29</sup>. Whole-genome sequencing was performed at baseline for  
363 all participants. Extensive phenotyping of the individuals was conducted every three months in the first

364 year and at approximately a 6-month interval in the second year, which included plasma metabolome  
365 and lipidome profiling, proteome profiling, clinical measurements, and detailed lifestyle questionnaires  
366 covering physical activity, mental health, substance intake, and other environmental factors, alongside  
367 blood sample collection, to capture seasonal fluctuations and provide a robust temporal perspective (**Fig.**  
368 **1a and Additional file 2: Table S1**). Using a combination of GC-MS and LC-MS technologies, we  
369 identified a total of 527 metabolites in the study. These metabolites were classified into nine main  
370 classes, covering a wide range of lipids (n = 335, 63.6%), amino acids (n = 77, 14.6%), xenobiotics (n  
371 = 37, 7.0%), peptides (n = 17, 3.2%), carbohydrates (n = 20, 3.8%), cofactors and vitamins (n = 16,  
372 3.0%), nucleotides (n = 14, 2.7%), energy (n = 7, 1.3%), and other metabolites (n = 4, 0.8%). The  
373 metabolites were further categorized into 63 subclasses based on their functions and biochemical  
374 characteristics (**Fig. 1a and Additional file 2: Table S2, see Methods for more details**).

375 To explore the co-expression patterns of these identified metabolites, we conducted a clustering analysis  
376 applying K-nearest neighbor (KNN), shared nearest neighbor (SNN) and Louvain algorithms and  
377 revealed that the 527 measured metabolites could be classified into eight major clusters (**Fig. 1b-c,**  
378 **Additional file 1: Fig. 1 and Additional file 2: Table S2**). Functional enrichment analysis based on  
379 customized class and pathway terms was further performed for each cluster to identify shared pathways  
380 among groups of co-expressed metabolites (**Fig. 1d and Additional file 2: Table S3**). Specifically,  
381 cluster 1 showed a co-regulation of pathways involved in fatty acid metabolism, including steroids and  
382 their derivatives, as well as monoglycerides. Cluster 2 mainly included metabolites related to the  
383 metabolism of dietary components such as caffeine and benzoates. Cluster 3 included pathways central  
384 to the urea cycle, specifically the arginine and proline metabolism. It also involved the metabolism of  
385 amino acids like methionine, cysteine, glycine, serine, and threonine, which are crucial for nitrogen  
386 balance and protein turnover<sup>61</sup>. Cluster 4 exhibited a co-expression similar to Cluster 3, featured by  
387 metabolites like dipeptides as well as the metabolisms of arginine, aspartate, and gamma-glutamyl  
388 amino acids, which are mainly involved in protein synthesis and amino acid recycling<sup>62</sup>. Cluster 5  
389 mainly consisted of metabolites essential for the cell membranes composition and signaling, including  
390 sphingomyelin, ceramide, and phosphatidylcholine<sup>63</sup>. Cluster 6 showed the interconnected pathways of



391 glycolysis, gluconeogenesis, and sugar metabolisms, including the metabolism of fructose, mannose,  
392 and galactose. Cluster 7 included metabolites related to energy storage and mobilization, such as  
393 triglycerides and diglycerides<sup>64</sup>. Cluster 8 comprises lyso-phosphatidylcholine, lyso-  
394 phosphatidylethanolamine, and phosphatidylcholine, key components involved in cell membrane  
395 remodeling<sup>65</sup>.

## 396 **Individual and seasonal variations in plasma metabolome profiles**

397 We assessed the variability in the expression of each metabolite over time by analyzing both inter-individual  
398 and intra-individual variations, calculated using the coefficient of variance (CV; **Fig. 2a and Additional file**  
399 **2: Table S4**). Notably, our analysis revealed that the variability between individuals for each measured  
400 metabolite was greater than the variability observed within the same individual, with ratios of inter-  
401 individual to intra-individual CV ranging from 1.09 to 8.86. Among these metabolites, pyrrole-2-carboxylic  
402 acid and picolinic acid showed the most significant differences between individuals (**Fig. 2a**). This suggests  
403 that, despite the fluctuations in each person's metabolic profile over time due to various environmental  
404 factors, each individual maintained a distinct metabolomic signature.

405 Interestingly, some metabolites showed seasonal patterns which partially contributed to the intra-individual  
406 variations. To explore the seasonal influences on metabolite variability and identify potential seasonal  
407 patterns, we performed an association analysis between metabolite levels and the month of sampling, with  
408 sex, age and BMI considered as covariates. A total of 121 metabolites showed clear associations with the  
409 month of sampling, with amplitudes ranging from 0.016 to 0.541 (**Fig. 2b and Additional file 2: Table S5**).  
410 Hierarchical clustering of these metabolites further showed four distinct seasonal patterns: extremely low  
411 levels from January to March (Cluster M1, n = 18); relatively low levels during the winter months (Cluster  
412 M2, n = 18); relatively high levels during winter (Cluster M3, n = 49); extremely high levels in December  
413 (Cluster M4, n = 36) (**Fig. 2c-g and Additional file 2: Table S6**). The metabolites in Cluster M1, exhibiting  
414 the lowest levels from January to March, were enriched in carbohydrate metabolism pathways (**Fig. 2h and**  
415 **Additional file 2: Table S7**). As an example, fructose reached its lowest levels in January and February  
416 (**Additional file 1: Fig. 2a**). This could reflect a post-holiday shift to baseline dietary habits or a reduction  
417 in the consumption of sugars. Conversely, the elevation of energy-related pathways in Cluster M4 during  
418 December may indicate an increased caloric intake during the festive period or an adaptive physiological



419 response to colder temperatures. Metabolites in Cluster M2, with relatively low levels in winter, were  
420 enriched in pathways associated with NAD<sup>+</sup> signaling, nicotinate and nicotinamide metabolism, purine  
421 metabolism, and phosphatidylethanolamine biosynthesis (**Fig. 2h**). This could reflect a reduced requirement  
422 for or availability of these pathways' end products during the winter, possibly due to changes in diet, reduced  
423 exposure to sunlight affecting vitamin D synthesis, which in turn affects NAD<sup>+</sup> synthesis<sup>66</sup>. Interestingly,  
424 the seasonal pattern of vitamin D closely correlated with the metabolites in Cluster M2 (Pearson  $P = 0.04827$ ,  
425 **Fig. 2i**). In contrast, Cluster M3 metabolites, which were relatively high during winter, were associated with  
426 amino acid metabolism, specifically glycine and serine metabolism, as well as pathways involved in  
427 ammonia recycling and the metabolism of methionine and homocysteine (**Fig. 2h**). For instance, the highest  
428 level of cysteine was observed during winter (**Additional file 1: Fig. 2b**). These increased levels of amino  
429 acid metabolism could suggest a shift in fuel utilization towards amino acid catabolism for energy production  
430 and could also be associated with lower levels of physical activity as reported by Pedersen EB, *et al*<sup>67</sup>.  
431 Interestingly, the energy metabolism-related fatty acid succinylcarnitine in Cluster M3, which is involved in  
432 carnitine synthesis and utilization pathway, also showed a significantly high inter-individual variation,  
433 indicating varying levels of energy metabolism among individuals (**Fig. 2j**).

434 We further analyzed the seasonal variations of plasma proteins and found that some plasma proteins also  
435 exhibited seasonal patterns, with two opposite seasonal clusters observed: Cluster P1, with low levels during  
436 the colder season (Cluster P1,  $n = 51$ ), and Cluster P2, with relatively low expression levels during the  
437 warmer months (Cluster P2,  $n = 312$ ) (**Additional file 1: Fig. 2c-e and Additional file 2: Table S8**). As an  
438 example, 46 proteins in Cluster P2 were found to closely correlate with the seasonal patterns of metabolites  
439 in Cluster M3. These proteins primarily function in amino acid, glycan, and fatty acid metabolism.  
440 Specifically, angiopoietin-like protein 4 (*ANGPTL4*), which regulates lipoprotein lipase and has been found  
441 to be influenced by dietary fatty acids in both human muscle<sup>68</sup> and mice heart<sup>69</sup>, showed associations with a  
442 group of fatty acids, such as cis-4-decenoylcarnitine and laurylcarnitine (**Additional file 1: Fig. 2f and 2g**).  
443 Along with these fatty acids, *ANGPTL4* exhibited relatively lower expression levels from June to September  
444 (**Additional file 1: Fig. 2h**). The associations between proteins and metabolites will be described in more  
445 depth below.

## 446 **Sex- and BMI-related divergences in plasma metabolite levels**

447 The associations between plasma metabolite concentrations, lifestyle factors and clinical measurements were  
448 analyzed using canonical correspondence analysis (CCA) that incorporated all 527 metabolites, 13 lifestyle  
449 variables, and 43 clinical chemistry and anthropometric variables across visits. Regression analysis of the  
450 two CCA components showed that CCA1 was mainly associated with BMI and lipid profiles, whereas CCA2  
451 was more closely related to sex, body composition (muscle and fat percentage), hemoglobin, and urate.  
452 Notably, a clear divergence between male and female samples was observed, emphasizing sex as a significant  
453 factor influencing plasma metabolomic levels (**Fig. 3a**). The associations between metabolites and sex were  
454 visualized in a volcano plot (**Fig. 3b and Additional file 2: Table S9**). Among the 119 metabolites that  
455 showed significant sex differences, 35 were found to be elevated in females and 84 were more abundant in  
456 males (**Fig. 3b**). In particular, the peptide gamma-glutamylleucine exhibited higher levels in males (**Fig. 3c**)  
457 and has been found to be associated with elevated cardio-metabolic risks<sup>70</sup>. Additionally, 86 BMI-related  
458 metabolites were identified (**Fig. 3d and Additional file 2: Table S10**), with glutamic acid showing the  
459 strongest association (**Fig. 3e**), which aligns with previous reports<sup>71</sup>. Furthermore, the ratio of glutamic acid  
460 to other amino acids, such as lysine, ornithine, and hydroxyproline, have been reported as promising  
461 biomarkers for identifying metabolically healthy obese individuals<sup>71</sup>. Interestingly, lifestyle factors such as  
462 physical activity, stress, and smoking were found to correlate with metabolite levels and show collinearity  
463 with sex. In general, the stress levels in females were higher than in males, which was also significantly  
464 associated with the elevation of the stress hormone corticosteroid<sup>72</sup>. On the other hands, a higher incidence  
465 of smoking among males was associated with the alterations in several metabolites, such as glutamine, which  
466 plays a central role in cellular metabolism and function, highlighting the influence of lifestyle factors on  
467 metabolic health.

## 468 **Genome-wide association analysis of the plasma metabolite profile**

469 To investigate the genetic influence on inter-individual differences in plasma metabolite concentration,  
470 a GWAS was performed based on individual variation coefficients for 527 plasma metabolites and 6.7  
471 million common genetic variants (minor allele frequency, MAF > 0.05) identified through whole-  
472 genome sequencing. A total of 66 significant associations between genetic variants and individual blood  
473 metabolite concentrations were identified ( $P < 2.17 \times 10^{-9}$ , conventional  $P$  of  $5 \times 10^{-8}$  adjusted for the

474 number of independent metabolites <sup>4</sup>). Among them, 19 independent metabolite quantitative trait loci  
475 (mQTLs) (Linkage Disequilibrium, LD,  $r^2 < 0.1$ , conditional  $P < 0.01$ ) involving 22 metabolites were  
476 identified (**Fig. 4a and Additional file 2: Table S11**). Of 19 mQTLs, 4 were pleiotropic genetic variants  
477 associated with multiple metabolites. Of these metabolites, 45% were lipids ( $n = 10$ ) (**Fig. 4a-b**). Out  
478 of the 22 genetically associated metabolites in our study, six have been previously analyzed in other  
479 GWAS studies<sup>4,7</sup>. To validate the associations between these metabolites and genetic variants, a meta-  
480 GWAS analysis was conducted for these six metabolites. Most of the genetic loci (8 out of 11) identified  
481 from meta-analysis showed the same direction of effects as in our study (**Additional file 2: Table S12**).  
482 Among these, the association between the genetic variant (rs34673751) from Acyl-CoA dehydrogenase  
483 short chain (*ACADS*) and butyrylcarnitine was the most significant in the meta-analysis. The *ACADS*  
484 gene encodes the enzyme short-chain acyl-CoA dehydrogenase (SCAD), which is essential for  
485 mitochondrial fatty acid beta-oxidation, while butyrylcarnitine is a short-chain acylcarnitine involved  
486 in fatty acid transport and energy metabolism. Our longitudinal analysis further demonstrated that  
487 individuals carrying A allele at rs34673751 exhibited stable higher blood butyrylcarnitine levels.  
488 Moreover, heterozygous individuals for the protein variant presented intermediate levels of blood  
489 butyrylcarnitine compared to the homozygous groups (**Fig. 4c-e**). To experimentally validate the  
490 association between *ACADS* and butyrylcarnitine, we knocked down the expression of *ACADS* in 293T  
491 cell lines using siRNA. Subsequent metabolite analysis revealed that silencing the *ACADS* gene  
492 increased the levels of butyrylcarnitine in these cells (**Fig. 4f-g**), providing direct evidence of *ACADS*'s  
493 role in the regulation of butyrylcarnitine levels.

494 Another notable example of the identified mQTLs is the association between metabolite 4-androsten-  
495 3alpha,17alpha-diol monosulfate (2), a sulfated steroid and a derivative of androstenediol, and the gene  
496 cytochrome P450 family 3 subfamily A member 7 (*CYP3A7*). (**Fig. 4h**). The highest association was  
497 found for the variant rs45446698, located upstream of the *CYP3A7* gene. Individuals carrying a TT  
498 homozygote had higher and more stable levels of 4-androsten-3alpha,17alpha-diol monosulfate (2) than  
499 individuals carrying a TG heterozygote (**Fig. 4i-j**).

## 500 **Quantification of genetic and non-genetic effects on plasma metabolite levels**

501 To quantify the influence of genetics, lifestyle, and physiological conditions on metabolite variability,  
502 we applied a linear multivariate regression model to each metabolite. This model included all 19 mQTLs,  
503 13 lifestyle factors, 43 anthropometric and clinical chemistry parameters, and visit. In the analysis, the  
504 genetic variants were combined as “genetic component”, all the lifestyle-related factors were combined  
505 as “lifestyle component”, and all anthropometric and clinical chemistry variables were categorized into  
506 13 clinical classes. A summary of the analysis across all 527 analyzed plasma metabolites (**Fig. 5a and**  
507 **Additional file 2: Table S13**) showed that the influence of genetics, lifestyle, and physiological  
508 conditions on plasma metabolite level varied considerably. Genetics emerged as one of the important  
509 factors; out of the 22 metabolites with at least one significant genetic association, 5 metabolites had a  
510 genetic contribution greater than 20% (**Fig. 5b**). The metabolite most affected by genetics was 1,3-  
511 Dimethylurate, which is formed from caffeine and can be used as an indicator of caffeine metabolism  
512 <sup>73</sup>, with 30% of its blood level variance explained by genetic variants. Besides genetics, 469 metabolites  
513 were influenced by various clinical factors, with a total contribution greater than 20%. Consistent with  
514 the CCA analysis (**Fig. 3a**), body composition and lipid profiles showed the most significant  
515 associations with plasma metabolite levels, with 69 metabolites associated with each of them. In  
516 addition, 54 metabolites were associated with urate levels, 48 with kidney function, 36 with glucose  
517 homeostasis, 18 with liver function, 17 with heart function, 15 with leukocytes, 6 with the acute phase  
518 response, and 28 with other clinical parameters. The top 25 most significant metabolites associated with  
519 clinical components were highlighted in **Fig. 5c**. As an example, a significant association was observed  
520 between body composition and pyroglutamylvaline, aligning with previous study that found  
521 pyroglutamylvaline to be positively associated with leg muscle<sup>74</sup>. Additionally, multiple metabolites  
522 have been identified as being associated with immune cell and red cell populations, as well as  
523 inflammatory biomarkers like C-reactive protein (CRP) (**Fig. 5c and Additional file 2: Table S13**).  
524 These results indicated the intricate crosstalk between metabolism, immune response, and  
525 hematopoiesis.

526 Furthermore, we identified 39 metabolites associated with various lifestyle factors, with 9 showing an  
527 influence from lifestyle factors greater than 20% (**Additional file 2: Table S13**). These lifestyle-related  
528 metabolites included 15 associated with smoking, 8 with changes in housing, 4 with physical activity,  
529 4 with stress, and 9 with other lifestyle factors. The top 25 most significant metabolites associated with  
530 lifestyle factors are listed in **Fig. 5d**. Notably, smoking had the most prominent influence on blood  
531 metabolite levels. Among the smoking associated metabolites, glutamine, the most abundant amino acid  
532 in the body and considered conditionally essential for critical illness and injury<sup>75,76</sup>, was negatively  
533 associated with smoking, along with factors such as 3-pyridinol, an intermediate product in nicotine  
534 degradation<sup>77</sup> (**Additional file 2: Table S13**).

### 535 **Individual metabolite-protein profiles in human plasma**

536 To investigate the co-expression patterns of plasma metabolites and proteins, we applied linear mixed  
537 modeling (LMM) to 527 metabolites and 794 proteins, adjusting for cofounders including subject, visit,  
538 sex, age, and BMI. The analysis revealed 5,649 significant protein-metabolite pairs, involving 479  
539 metabolites and 625 proteins, each characterized by a correlation with a false discovery rate (FDR)  
540 adjusted  $P$  of less than 0.05 (**Additional file 2: Table S14**). Among these significant associations, 459  
541 involving 121 metabolites and 257 proteins (48.93% of the overlapping metabolite-protein associations)  
542 aligned with previous findings from Benson MD, et al.<sup>78</sup>, despite differences in molecular measurement  
543 platforms. In **Fig. 6a** we present the 200 most significant protein-metabolite associations to illustrate  
544 the complex interplay within the protein-metabolite network. Multiple important hormones, enzymes,  
545 receptors and cytokines, such as glucagon (GCG), lipoprotein lipase (LPL), natriuretic peptide (NPPC),  
546 and interleukin 10 (IL10), have been identified as hub proteins in the network, highlighting their broad  
547 regulatory roles in human metabolism. Most of these protein-metabolite associations were connected  
548 to lifestyle and physiological conditions. As an example, we found a co-regulation between leptin (LEP)  
549 and aceturic acid (**Fig. 6b**). LEP, a hormone secreted by adipose tissue, plays an important role in  
550 regulating hunger and energy balance<sup>79</sup>, with higher concentrations observed in females<sup>80</sup>. Aceturic acid,  
551 also known as N-acetylglycine, is a derivative of the amino acid glycine and has been reported to

552 modulate weight and associated adipose tissue immunity<sup>81</sup>. Our findings suggested a significant  
553 interaction between LEP and acetic acid with gender stratification.

554 Subsequent Mendelian Randomization (MR) analyses were conducted to investigate potential genetic  
555 drivers of causality between plasma proteins and metabolites. A total of 87 putative causal associations  
556 were identified between 38 proteins and 61 metabolites (FDR-adjusted  $P < 0.05$ , **Additional file 1: Fig.**  
557 **3a, Additional file 2: Table S15**). As an example, we detected a significant MR association between  
558 MDGA1, a cell surface glycoprotein involved in cell adhesion, migration, axon guidance, and  
559 neurodevelopment<sup>82-84</sup>, and 1-Arachidonoylglycerol (1-AG) (**Fig. 6c**), a stable regioisomer of the  
560 endocannabinoid 2-AG engaged in physiological functions such as emotion, cognition, and  
561 neuroinflammation<sup>85,86</sup>. Our analyses showed that the cis instrumental variable (rs9349050, **Fig. 6d**) for  
562 the MDGA1 protein consistently differentiated both MDGA1 and 1-AG levels in individuals carrying  
563 different genotypes (**Additional file 1: Fig. 3b-c**). This stable and positive association between  
564 MDGA1 and 1-AG indicated a potential genetic basis for the co-regulation of proteins and metabolites  
565 in the nervous system.

566 Using Uniform Manifold Approximation and Projection (UMAP), we clustered the individual  
567 molecular profiles based on the integrated metabolite-protein network. We noted that each individual  
568 possessed a unique and stable protein-metabolic profile (**Fig. 6e**). Regression analysis of the two UMAP  
569 components (**Fig. 6f-g**) revealed that UMAP1 was most significantly associated with genetic factors,  
570 followed by kidney function, lipid profile, body composition and erythrocytes. UMAP2 showed  
571 significant associations with body composition, blood pressure, genetics, and erythrocytes. Additionally,  
572 immune response, vitamin D, urate levels, liver functions, glucose homeostasis were moderately  
573 associated with the metabolite-protein profiles. Lifestyle factors such as stress, drug intake, smoking,  
574 and physical activity also exhibited minor influences on these profiles.

575 To identify key proteins and metabolites with the highest connectivity of the protein-metabolite network,  
576 we quantified their importance using the centrality betweenness score and categorized them into three  
577 tiers based on their deviation from the median level, measured in median absolute deviations (MAD).  
578 These categories include Tier 1, high importance (beyond two MADs); Tier 2, moderate importance

579 (beyond one MAD); and Other: low importance (within one MAD). (**Fig 6 h-i**). Notably, *ANGPTL4*  
580 and *LEP* were the top two proteins with the highest scores (**Fig. 6j**). *ANGPTL4* has been reported as a  
581 key regulator in lipid metabolism, primarily by inhibiting the activity of lipoprotein lipase (*LPL*)<sup>87</sup>, and  
582 also involved in angiogenesis, vascular permeability, and inflammation processes. In our analysis, we  
583 revealed that *ANGPTL4* was associated with a broad spectrum of metabolites, involving those related  
584 to lipid and glucose metabolism, tissue functions, and immune responses (**Additional file 1: Fig. 3d**).  
585 *LEP*, which is a well-known hormone, has been shown in recent studies to reflect systemic alterations  
586 of the human metabolome<sup>88,89</sup>. In our analysis, we observed that *LEP* was associated with a spectrum  
587 of metabolites related to blood pressure and glucose homeostasis, as well as stress (**Additional file 1:**  
588 **Fig. 3d**). On the other hand, N-Acetylaspartate (NAA), one of the most abundant metabolites in the  
589 mammalian brain, and 3-Hydroxyhippurate, a microbial aromatic acid metabolite derived from dietary  
590 polyphenols and flavonoids found in normal human urine, were identified as high-importance  
591 metabolites through network analysis and found to be associated with kidney function in the study (**Fig.**  
592 **6k, Additional file 2: Table S13**).

### 593 **Variability of protein-metabolite profiles and the associations with metabolic health**

594 To investigate the associations between protein-metabolite profile variability and metabolic health, we  
595 stratified the analyzed samples into two risk groups (high-risk group and low-risk group) based on the  
596 clustering patterns of five key indicators of metabolic syndrome: high density lipoprotein (HDL), body  
597 mass index (BMI), systolic blood pressure (SBP), triglycerides (TG) and fasting glucose (Gluc)<sup>90</sup>. The  
598 high-risk group was characterized by increased levels of BMI, SBP, TG, and Gluc, alongside decreased  
599 levels of HDL, in comparison with the low-risk group (**Fig. 7a**). We then explored the differences in  
600 clinical chemistry measurements between these two groups. We found significant higher levels of two  
601 liver function biomarkers (alanine aminotransferase, ALAT; gamma glutamyltransferase, GGT), one  
602 kidney function biomarker (urate), one heart function biomarker (troponin T, TNT), and one immune  
603 biomarker (white blood cells count, WBC) in the high-risk group, indicating an increased susceptibility  
604 to cardiometabolic diseases (**Fig. 7b**).



605 Predictive modeling of the metabolic risk of the analyzed samples was conducted using proteins and  
606 metabolites. Interestingly, we found that the predictive power for risk groups, based on a combination  
607 of all proteins and metabolites, to be comparable to that based on Tier 1 proteins (n = 13) and metabolites  
608 (n = 14) alone, as well as models based on only proteins (**Fig. 7c,d**). This highlighted the potential  
609 importance of Tier 1 proteins and metabolites for metabolic risk assessments. In addition, proteins  
610 contributed more significantly to metabolic risk prediction than metabolites, with metabolites providing  
611 only marginal additional predictive value. Remarkably, the predictive power of Tier 1 proteins alone  
612 approached that of the full protein model (**Fig. 7c,d**), while metabolites demonstrated considerably  
613 lower predictive power compared to proteins (**Fig. 7c,d**). The importance of Tier 1 proteins and  
614 metabolites in relation to metabolic risk was quantified using a linear regression model to estimate the  
615 impact coefficients (**Fig. 7e,f**). We further examined the expressions levels of the 13 Tier 1 proteins in  
616 individuals with metabolic diseases, including obesity, type 2 diabetes (T2D), gout or hyperthyroidism,  
617 compared to healthy individuals using data from the UK Biobank<sup>49</sup>. Our analysis revealed that the  
618 expression levels of all Tier 1 proteins were significantly different ( $P < 0.05$ ) between healthy individuals  
619 and those diagnosed with any of these metabolic diseases (**Fig. 7g, Additional file 1: Fig. 4**).  
620 Furthermore, the expression patterns of these 13 Tier 1 proteins varied significantly across different  
621 metabolic diseases, indicating their potential use as diagnostic biomarkers for various metabolic  
622 conditions. Moreover, we assessed the predictive power of Tier 1 proteins for these metabolic diseases,  
623 resulting in average AUCs ranging from 0.643 and 0.878 across different diseases (**Fig. 7h**).

624 Next, we examined the stability of the risk levels of participants throughout the two-year study. In  
625 general, the metabolic health status of most participants (70 out of 101) remained consistent, with 39  
626 categorized within the high-risk group and 31 within the low-risk group at every visit (**Fig. 7i**). A notable  
627 exceptional case was participant W0010, who experienced a significant weight reduction from 120 kg  
628 during the third visit to 104.7 kg by the fourth visit (**Fig. 7j**). This remarkable change caused a shift  
629 from the high-risk group in the initial three visits to the low-risk group in the subsequent three  
630 assessments. Focusing on the Tier 1 proteins, we observed a significant decrease in their levels from  
631 the third to the fourth visit (**Fig. 7k**). However, between the fourth and sixth visits, protein levels



632 reversed despite no significant change in BMI (**Fig. 7k**), suggesting alterations in the individual's  
633 underlying metabolism at the molecular level. Additionally, we found that nearly half of the Tier 1  
634 proteins (6 / 13) displayed significantly different levels between lean (BMI < 25) and obese (BMI > 30)  
635 groups (**Additional file 1: Fig. 5**). We further predicted future obesity in individuals with a baseline  
636 BMI lower than 25 in the UK Biobank using the 13 Tier 1 protein expressions. The results showed that  
637 participants who later developed obesity (BMI > 30) already exhibited a distinct profile of Tier 1  
638 proteins at baseline compared to those who maintained a BMI lower than 30 throughout the study period  
639 (**Additional file 1: Fig. 6a, b**). Predictive models demonstrated that baseline expression levels of Tier  
640 1 proteins could predict future obesity with an average AUC of 0.773 with a 95% confidence interval  
641 of 0.739-0.806 (**Fig. 7l**).

## 642 **Discussion**

643 In this study, we have performed a longitudinal multi-omics analysis on a group of clinically healthy  
644 participants aged 55 to 65 over two years to explore how genetics, lifestyle and physiological conditions  
645 affect individual metabolic profiles. We systematically examined the abundances and dynamics of 527  
646 blood metabolites, which were categorized into nine major classes: lipids, amino acids, xenobiotics,  
647 peptides, carbohydrates, cofactors and vitamins, nucleotides, energy, and others. These metabolites  
648 were analyzed alongside their co-regulations with 794 proteins. By integrating whole-genome  
649 sequencing and extensive phenotyping data collected concurrently at each sampling time point, our  
650 results revealed an intricate interplay between genetic predispositions and environmental factors in  
651 shaping individual metabolic profiles.

652 One unique aspect of our study is the focus on the temporal dynamics of individual metabolic profiles.  
653 We identified eight co-expressed metabolite clusters based on longitudinal data and linked them to  
654 various metabolic pathways that are susceptible to both internal and external modulators, such as energy  
655 mobilization and dietary intake. By analyzing intra-individual metabolite variation over time, we  
656 observed four distinct seasonal patterns of plasma metabolites, with more fluctuations or extreme  
657 concentrations during the summer and winter. These seasonal fluctuations of metabolites might reflect  
658 changes in physical activity<sup>67</sup>, diet<sup>91</sup>, and metabolic rate<sup>92</sup>, which are closely related to the season and

659 might be regulated by seasonal gene expressions in multiple tissue types, including adipose tissue, brain,  
660 and gonadal tissue<sup>93,94</sup>. Similar seasonal variations were observed in the proteomics profiling,  
661 suggesting a coordinated seasonal influence on both metabolite and protein levels.

662 In general, our analysis revealed higher inter-individual variations than intra-individual variations in  
663 plasma metabolite levels. By integrating whole-genome sequencing, we identified significant  
664 associations between genetic variants and blood metabolite levels (mQTLs). Numerous mQTLs have  
665 been identified within various populations<sup>8-13,95</sup>, and in this study, we used individual coefficients  
666 obtained from longitudinal data to better associate metabolite levels with genetic factors. Considering  
667 the significant seasonal variations observed in metabolite levels, this approach allows for more accurate  
668 quantification of individual metabolite levels for mQTL identification. Our findings indicated that many  
669 plasma metabolite levels during adult life were genetically predetermined at birth and remained stable  
670 within a range of dynamics under healthy conditions. Additionally, our results showed that lifestyle and  
671 clinical factors also significantly contributed to the variability in blood metabolite levels. Notably, 89%  
672 of (469 out of 527) metabolites exhibited at least a 20% variability attributable to lifestyle or clinical  
673 factors, indicating a substantial influence from lifestyle and physiological conditions on human  
674 metabolism. Among these, body composition and smoking were the top physiological and lifestyle  
675 factors influencing blood metabolite levels.

676 Proteins, as essential regulators and executors of metabolic processes, are critical components of human  
677 metabolic profiles, making their analysis essential for a comprehensive understanding of human  
678 metabolism. By integrating longitudinal metabolomics and proteomics data from the same individuals,  
679 we established a protein-metabolite co-expression network and found that each individual possessed a  
680 unique and stable protein-metabolic profile over time. This stability of individuals' protein-metabolite  
681 profiles suggested that, despite the changes in environment, there is an inherent individuality to  
682 metabolic regulation. Our analysis showed that genetic factors were the most significant contributors to  
683 these profiles, with additional moderate influences from physiological conditions such as kidney  
684 function, blood pressure, and body compositions. Moreover, lifestyle factors like stress, smoking, and  
685 drug intake also had considerable impacts.

686 Furthermore, we identified key signature proteins and metabolites that characterize individual protein-  
687 metabolic profiles and assessed the predictive power of the most important Tier 1 proteins and  
688 metabolites for identifying individuals at high metabolic risk. Remarkably, the predictive performance  
689 of these Tier 1 biomarkers was comparable to that of the full set of proteins and metabolites,  
690 underscoring their potential utility in metabolic health monitoring. This finding also revealed a superior  
691 predictive power of proteins over metabolites. This is likely because proteins are directly involved in  
692 essential metabolic processes, function as signaling molecules and regulators, and generally exhibit  
693 greater stability and consistency over time. In our previous report, we also showed that plasma proteome  
694 exhibited most of the effects from clinical data<sup>34,33</sup>. We further validated this panel of 13 Tier 1 proteins  
695 in large-scale population data from the UK Biobank for the prediction of metabolic diseases. These  
696 biomarkers showed significant potential in diagnosing metabolic diseases. Although, all of the 13  
697 proteins were elevated in various metabolic diseases, they exhibited different patterns in different  
698 metabolic abnormalities. Interestingly, we observed that the levels of the 13 proteins in an obese  
699 individual in the S3WP study initially decreased following weight loss but subsequently started to revert  
700 to the initial levels, despite a stable BMI during the study period. In the UK Biobank, we also noted that  
701 individuals who eventually became obese already exhibited an altered profile of Tier 1 proteins at a  
702 normal BMI and at baseline. These observations suggest that fluctuations in the proteome may precede  
703 BMI changes, highlighting their potential value in weight management strategies. However, it should  
704 be noted that more comprehensive analyses in large disease cohorts of these plasma proteins and  
705 metabolites must be performed to validate their use as clinical biomarkers. Another limitation of this  
706 study is the relatively small cohort size, which may not capture the full spectrum of individual metabolic  
707 variability across diverse populations. Thus, further validation and generalization of the findings in  
708 larger, more diverse cohorts and in clinical settings are necessary.

## 709 **Conclusions**

710 In summary, our study provides a comprehensive longitudinal analysis on how genetics, lifestyle, and  
711 physiological factors influence the human metabolic profiles. Our results demonstrated the dynamic  
712 interplay between genetic predispositions and environmental factors, including seasonal variations,

713 lifestyle, and physiological changes. By integrating proteomics and metabolomics data, we established  
714 a detailed protein-metabolite network and identified key molecular signatures that enhanced metabolic  
715 disease diagnostics and risk assessments. These findings offer promising avenues for improving  
716 metabolic health monitoring and developing future targeted interventions based on an individual's  
717 unique metabolic profile.

## 718 **Abbreviations**

719 **1-AG:** 1-Arachidonoylglycerol

720 **ACADS:** Acyl-CoA dehydrogenase short chain

721 **ALAT:** Alanine aminotransferase

722 **ANGPTL4:** Angiotensin-like protein 4

723 **ANOVA:** Analysis of Variance

724 **ApoA1:** Apolipoprotein A1

725 **ApoB:** Apolipoprotein B

726 **AUC:** Area under curve

727 **BMI:** Body mass index

728 **CCA:** Canonical correspondence analysis

729 **CRP:** C-reactive protein

730 **CV:** Coefficient of variance

731 **CYP3A7:** Cytochrome P450 family 3 subfamily A member 7

732 **FDR:** False discovery rate

733 **GCG:** Glucagon

734 **GC-MS:** Gas chromatography-mass spectrometry

735 **GGT:** Gamma glutamyltransferase

736 **Gluc:** Fasting glucose

737 **GWAS:** Genome-wide association studies

738 **HDL:** High density lipoprotein

739 **HMDB:** Human Metabolomics Database

740 **IL10:** Interleukin 10  
741 **IV:** Instrumental variable  
742 **KNN:** K-nearest neighbor  
743 **LC-MS:** Liquid chromatography-mass spectrometry  
744 **LD:** Linkage Disequilibrium  
745 **LDL:** Low density lipoprotein  
746 **LEP:** Leptin  
747 **LMM:** Linear mixed modeling  
748 **LPL:** Lipoprotein lipase  
749 **MAD:** Median absolute deviation  
750 **MAF:** Minor allele frequency  
751 **MDGA1:** MAM domain containing glycosylphosphatidylinositol anchor 1  
752 **mQTL:** Metabolite quantitative trait loci  
753 **MR:** Mendelian randomization  
754 **NAD+:** Nicotinamide adenine dinucleotide+  
755 **NPPC:** Natriuretic peptide  
756 **NPX:** Normalized Protein eXpression  
757 **NTproBNP:** N-Terminal pro-brain natriuretic peptide  
758 **pQTL:** Protein quantitative trait locus  
759 **QC:** Quality control  
760 **Q-TOF:** Quadrupole Time-of-Flight  
761 **ROC:** Receiver operating characteristic  
762 **S3WP:** Swedish SciLifeLab SCAPIS Wellness Profiling  
763 **SBP:** Systolic blood pressure  
764 **SCAD:** Short-chain acyl-CoA dehydrogenase  
765 **SCAPIS:** Swedish CARdioPulmonary bioImage Study  
766 **siRNA:** short interfering RNA  
767 **SMPDB:** Small Molecule Pathway Database

768 **SNN:** Shared nearest neighbor  
769 **SNP:** Single-nucleotide polymorphism  
770 **T2D:** Type 2 diabetes  
771 **TG:** Triglyceride  
772 **TNT:** Troponin T  
773 **UMAP:** Uniform manifold approximation and projection  
774 **WBC:** White blood cells count

775

## 776 **Declarations**

### 777 **Ethics approval and consent to participate**

778 The Swedish SciLifeLab SCAPIS Wellness Profiling (S3WP) study has been approved by the Ethical  
779 Review Board of Göteborg, Sweden (registration number 407-15), and all participants provided written  
780 informed consent. The study protocol adheres to the ethical guidelines outlined in the 1975 Declaration  
781 of Helsinki.

### 782 **Consent for publication**

783 Not applicable.

### 784 **Availability of data and materials**

785 This study utilized participant-level datasets that have been securely deposited at the Swedish National  
786 Data Service (SND), a repository certified by the Core Trust Seal (URL: <https://snd.gu.se/>). The GC  
787 and LC-MS datasets are available as part of the full SW3P Wellness multi-omics dataset with the doi  
788 10.5878/rdys-mz27. In compliance with patient consent and confidentiality agreements, these datasets  
789 are accessible for validation purposes only. Requests for access can be directed to SND via email  
790 ([snd@snd.gu.se](mailto:snd@snd.gu.se)). The evaluation of such requests will be conducted in accordance with relevant  
791 Swedish legislation. Additionally, for inquiries specifically on research within the scope of the S3WP  
792 program, interested parties are encouraged to contact the corresponding author directly. The code can  
793 be made available upon request to the corresponding author.

794 **Competing interests**

795 The authors declare no competing interests.

796 **Funding**

797 This work was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant:  
798 KAW 2020.0239) and the Swedish Research Council (#2022-01562).

799 **Authors' contributions**

800 W.Z. conceived and designed the study. G.B. supplied clinical material. M.U., G.B., W.Z. and F.E.,  
801 collected and contributed data to the study. W.Z., J.W., A.Z., and X.W. performed the data analysis.  
802 W.Z., J.W., A.Z., and X.W. drafted the manuscript. All authors read and approved the final manuscript.

803 **Acknowledgements**

804 Original human sensitive data was processed under Project sens2018115. The integrative multi-omics  
805 analysis of the processed data was performed using computational resources provided by SNIC through  
806 the Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project  
807 Berzelius-2024-200. Part of this research was conducted using the UK Biobank Resource under  
808 Application 99914. We thank the Plasma Profiling Facility at SciLifeLab in Stockholm for conducting  
809 the Olink analyses and Dr. Linn Fagerberg for data collection and data analysis in the S3WP program.  
810 We also thank the Proteomics and Metabolomics Platform at Guangzhou Laboratory for conducting the  
811 cell-line validation experiment using liquid chromatography-time-of-flight mass spectrometry (Q-TOF).  
812 We also express our gratitude to Yanfen Hong for her assistance with data acquisition and analysis.

813 **Authors' information**

814 Science for Life Laboratory, Department of Biomedical and Clinical Sciences (BKV), Linköping  
815 University, Linköping, Sweden.

816 Jing Wang, Alberto Zenere, Xingyue Wang and Wen Zhong

817

818 Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, and  
819 Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

820 Göran Bergström

821

822 Department of Protein Science, KTH - Royal Institute of Technology, Stockholm, Sweden

823 Fredrik Edfors and Mathias Uhlén

## 824 **References**

825 1. Gieger, C. *et al.* Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite  
826 Profiles in Human Serum. *PLoS Genet.* **4**, e1000282 (2008).

827 2. Chen, L. *et al.* Influence of the microbiome, diet and genetics on inter-individual variation in the  
828 human plasma metabolome. *Nat. Med.* **28**, 2333–2343 (2022).

829 3. Robinson, J. L. *et al.* An Atlas of Human Metabolism. *Sci. Signal.* **13**, eaaz1482 (2020).

830 4. Chen, Y. *et al.* Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human  
831 diseases. *Nat. Genet.* **55**, 44–53 (2023).

832 5. Hornburg, D. *et al.* Dynamic lipidome alterations associated with human health, disease and ageing.  
833 *Nat. Metab.* **5**, 1578–1594 (2023).

834 6. Merino, J., Udler, M. S., Leong, A. & Meigs, J. B. A Decade of Genetic and Metabolomic  
835 Contributions to Type 2 Diabetes Risk Prediction. *Curr. Diab. Rep.* **17**, 135 (2017).

836 7. Shin, S.-Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat. Genet.* **46**, 543–  
837 550 (2014).

838 8. Long, T. *et al.* Whole-genome sequencing identifies common-to-rare variants associated with human  
839 blood metabolites. *Nat. Genet.* **49**, 568–578 (2017).

840 9. Surendran, P. *et al.* Rare and common genetic determinants of metabolic individuality and their  
841 effects on human health. *Nat. Med.* **28**, 2321–2332 (2022).

842 10. Lotta, L. A. *et al.* A cross-platform approach identifies genetic regulators of human metabolism  
843 and health. *Nat. Genet.* **53**, 54–64 (2021).

844 11. Illig, T. *et al.* A genome-wide perspective of genetic variation in human metabolism. *Nat. Genet.*  
845 **42**, 137–141 (2010).



- 846 12. Bomba, L. *et al.* Whole-exome sequencing identifies rare genetic variants associated with  
847 human plasma metabolites. *Am. J. Hum. Genet.* **109**, 1038–1054 (2022).
- 848 13. Karjalainen, M. K. *et al.* Genome-wide characterization of circulating metabolic biomarkers.  
849 *Nature* 1–9 (2024) doi:10.1038/s41586-024-07148-y.
- 850 14. Cirulli, E. T. *et al.* Profound Perturbation of the Metabolome in Obesity Is Associated with  
851 Health Risk. *Cell Metab.* **29**, 488-500.e2 (2019).
- 852 15. Watanabe, K. *et al.* Multiomic signatures of body mass index identify heterogeneous health  
853 phenotypes and responses to a lifestyle intervention. *Nat. Med.* **29**, 996–1008 (2023).
- 854 16. Ottosson, F. *et al.* Metabolome-Defined Obesity and the Risk of Future Type 2 Diabetes and  
855 Mortality. *Diabetes Care* **45**, 1260–1267 (2022).
- 856 17. Xu, T. *et al.* Effects of smoking and smoking cessation on human serum metabolite profile:  
857 results from the KORA cohort study. *BMC Med.* **11**, 60 (2013).
- 858 18. Bar, N. *et al.* A reference map of potential determinants for the human serum metabolome.  
859 *Nature* **588**, 135–140 (2020).
- 860 19. Asnicar, F. *et al.* Microbiome connections with host metabolism and habitual diet from 1,098  
861 deeply phenotyped individuals. *Nat. Med.* **27**, 321–332 (2021).
- 862 20. Altmaier, E. *et al.* Metabolomics approach reveals effects of antihypertensives and lipid-  
863 lowering drugs on the human metabolism. *Eur. J. Epidemiol.* **29**, 325–336 (2014).
- 864 21. Chen, L. *et al.* Influence of the microbiome, diet and genetics on inter-individual variation in  
865 the human plasma metabolome. *Nat. Med.* **28**, 2333–2343 (2022).
- 866 22. Stamp, T. C. B. & Round, J. M. Seasonal Changes in Human Plasma Levels of 25-  
867 Hydroxyvitamin D. *Nature* **247**, 563–565 (1974).
- 868 23. Brewerton, T. D., Putnam, K. T., Lewine, R. R. J. & Risch, S. C. Seasonality of cerebrospinal  
869 fluid monoamine metabolite concentrations and their associations with meteorological variables in  
870 humans. *J. Psychiatr. Res.* **99**, 76–82 (2018).
- 871 24. Martynova, E. *et al.* Seasonal Changes in Serum Metabolites in Multiple Sclerosis Relapse. *Int.*  
872 *J. Mol. Sci.* **24**, 3542 (2023).

- 873 25. Ma, Y. *et al.* Seasonal variation in food intake, physical activity, and body weight in a  
874 predominantly overweight population. *Eur. J. Clin. Nutr.* **60**, 519–528 (2006).
- 875 26. Küçükerdönmez, Ö. & Rakicioğlu, N. The effect of seasonal variations on food consumption,  
876 dietary habits, anthropometric measurements and serum vitamin levels of university students. *Prog.*  
877 *Nutr.* **20**, (2018).
- 878 27. Chaleckis, R., Murakami, I., Takada, J., Kondoh, H. & Yanagida, M. Individual variability in  
879 human blood metabolites identifies age-related differences. *Proc. Natl. Acad. Sci.* **113**, 4252–4259  
880 (2016).
- 881 28. Chen, Z.-Z. *et al.* Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment  
882 Effect in the Diabetes Prevention Program. *Diabetes* **68**, 2337–2349 (2019).
- 883 29. Tebani, A. *et al.* Integration of molecular profiles in a longitudinal wellness profiling cohort.  
884 *Nat. Commun.* **11**, 4487 (2020).
- 885 30. Kim, K. *et al.* Mealtime, temporal, and daily variability of the human urinary and plasma  
886 metabolomes in a tightly controlled environment. *PLoS One* **9**, e86223 (2014).
- 887 31. Ala-Korpela, M. *et al.* Cross-sectionally Calculated Metabolic Aging Does Not Relate to  
888 Longitudinal Metabolic Changes-Support for Stratified Aging Models. *J. Clin. Endocrinol. Metab.*  
889 **108**, 2099–2104 (2023).
- 890 32. Bergström, G. *et al.* The Swedish CARDioPulmonary BioImage Study: objectives and design. *J.*  
891 *Intern. Med.* **278**, 645–659 (2015).
- 892 33. Zhong, W. *et al.* Next generation plasma proteome profiling to monitor health and disease. *Nat.*  
893 *Commun.* **12**, 2493 (2021).
- 894 34. Zhong, W. *et al.* Whole-genome sequence association analysis of blood proteins in a  
895 longitudinal wellness cohort. *Genome Med.* **12**, 53 (2020).
- 896 35. Danecek, P. & McCarthy, S. A. BCFtools/csq: haplotype-aware variant consequences.  
897 *Bioinformatics* **33**, 2037–2039 (2017).
- 898 36. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer  
899 datasets. *GigaScience* **4**, 7 (2015).

- 900 37. McLaren, W. *et al.* Deriving the consequences of genomic variants with the Ensembl API and  
901 SNP Effect Predictor. *Bioinformatics* **26**, 2069–2070 (2010).
- 902 38. Diab, J. *et al.* Lipidomics in Ulcerative Colitis Reveal Alteration in Mucosal Lipid Composition  
903 Associated With the Disease State. *Inflamm. Bowel Dis.* **25**, 1780–1787 (2019).
- 904 39. Wishart, D. S. *et al.* HMDB 5.0: the Human Metabolome Database for 2022. *Nucleic Acids Res.*  
905 **50**, D622–D631 (2022).
- 906 40. Arya, S., Mount, D., Kemp, S. E. & Jefferis, G. RANN: Fast Nearest Neighbour Search (Wraps  
907 ANN Library) Using L2 Metric. (2019).
- 908 41. Hahsler, M., Piekenbrock, M. & Doran, D. dbscan: Fast Density-Based Clustering with R. *J.*  
909 *Stat. Softw.* **91**, 1–30 (2019).
- 910 42. Csárdi, G. *et al.* igraph: Network Analysis and Visualization. (2024).
- 911 43. Hinrichs, A. S. *et al.* The UCSC Genome Browser Database: update 2006. *Nucleic Acids Res.*  
912 **34**, D590–D598 (2006).
- 913 44. Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. *BMC*  
914 *Bioinformatics* **11**, 288 (2010).
- 915 45. Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest Package: Tests in Linear  
916 Mixed Effects Models. *J. Stat. Softw.* **82**, 1–26 (2017).
- 917 46. Halekoh, U. & Højsgaard, S. A Kenward-Roger Approximation and Parametric Bootstrap  
918 Methods for Tests in Linear Mixed Models – The R Package pbkrtest. *J. Stat. Softw.* **59**, 1–32 (2014).
- 919 47. Kleiber, C. & Zeileis, A. AER: Applied Econometrics with R. Springer-Verlag (2008).
- 920 48. R Core Team and contributors worldwide. The R Stats Package.
- 921 49. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK Biobank.  
922 *Nature* **622**, 329–338 (2023).
- 923 50. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*  
924 **562**, 203–209 (2018).
- 925 51. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. in *Proceedings of the*  
926 *22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* 785–794  
927 (Association for Computing Machinery, New York, NY, USA, 2016). doi:10.1145/2939672.2939785.

- 928 52. Laboratory, N.-R. A. verification: Weather Forecast Verification Utilities. (2015).
- 929 53. McInnes, L., Healy, J., Saul, N. & Großberger, L. UMAP: Uniform Manifold Approximation  
930 and Projection. *J. Open Source Softw.* **3**, 861 (2018).
- 931 54. Oksanen, J. *et al.* vegan: Community Ecology Package. (2022).
- 932 55. Allaire, J. J. *et al.* networkD3: D3 JavaScript Network Graphs from R. (2017).
- 933 56. Kolde, R. pheatmap: Pretty Heatmaps. (2019).
- 934 57. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular  
935 visualization in R. *Bioinforma. Oxf. Engl.* **30**, 2811–2812 (2014).
- 936 58. Read, Q. D. & Brunson, J. C. ggalluvial: Alluvial Plots in ‘ggplot2’. (2023).
- 937 59. Wickham, H. ggplot2. *WIREs Comput. Stat.* **3**, 180–185 (2011).
- 938 60. Team, R. R: A language and environment for statistical computing. *MSOR Connect.* (2014).
- 939 61. Wu, G. Amino acids: metabolism, functions, and nutrition. *Amino Acids* **37**, 1–17 (2009).
- 940 62. DeBerardinis, R. J. *et al.* Beyond aerobic glycolysis: Transformed cells can engage in glutamine  
941 metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc. Natl. Acad. Sci.*  
942 **104**, 19345–19350 (2007).
- 943 63. Rodriguez-Cuenca, S., Pellegrinelli, V., Campbell, M., Oresic, M. & Vidal-Puig, A.  
944 Sphingolipids and glycerophospholipids - The ‘ying and yang’ of lipotoxicity in metabolic diseases.  
945 *Prog. Lipid Res.* **66**, 14–29 (2017).
- 946 64. Grabner, G. F., Xie, H., Schweiger, M. & Zechner, R. Lipolysis: cellular mechanisms for lipid  
947 mobilization from fat stores. *Nat. Metab.* **3**, 1445–1465 (2021).
- 948 65. McMahon, H. T. & Gallop, J. L. Membrane curvature and mechanisms of dynamic cell  
949 membrane remodelling. *Nature* **438**, 590–596 (2005).
- 950 66. Chang, E. & Kim, Y. Vitamin D decreases adipocyte lipid storage and increases NAD-SIRT1  
951 pathway in 3T3-L1 adipocytes. *Nutr. Burbank Los Angel. Cty. Calif* **32**, 702–708 (2016).
- 952 67. Pedersen, E. B. *et al.* Plasma amino acids in Greenlanders and Danes: influence of seasons,  
953 residence, ethnicity, and diet. *Am. J. Hum. Biol. Off. J. Hum. Biol. Counc.* **18**, 99–111 (2006).
- 954 68. Catoire, M. *et al.* Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise.  
955 *Proc. Natl. Acad. Sci. U. S. A.* **111**, E1043-1052 (2014).

- 956 69. A, G. *et al.* Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome  
957 proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress.  
958 *Circ. Res.* **106**, (2010).
- 959 70. Wu, Q. *et al.* Gamma-glutamyl-leucine levels are causally associated with elevated cardio-  
960 metabolic risks. *Front. Nutr.* **9**, 936220 (2022).
- 961 71. Badoud, F. *et al.* Serum and adipose tissue amino acid homeostasis in the metabolically healthy  
962 obese. *J. Proteome Res.* **13**, 3455–3466 (2014).
- 963 72. Teo, C. H., Wong, A. C. H., Sivakumaran, R. N., Parhar, I. & Soga, T. Gender Differences in  
964 Cortisol and Cortisol Receptors in Depression: A Narrative Review. *Int. J. Mol. Sci.* **24**, 7129 (2023).
- 965 73. Aranda, J. V. *et al.* Metabolism of Theophylline to Caffeine in Human Fetal Liver. *Science* **206**,  
966 1319–1321 (1979).
- 967 74. Diamanti, K. *et al.* Integration of whole-body [18F]FDG PET/MRI with non-targeted  
968 metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes. *Sci.*  
969 *Rep.* **10**, 8343 (2020).
- 970 75. Oudemans-van Straaten, H. M., Bosman, R. J., Treskes, M., van der Spoel, H. J. & Zandstra,  
971 D. F. Plasma glutamine depletion and patient outcome in acute ICU admissions. *Intensive Care Med.*  
972 **27**, 84–90 (2001).
- 973 76. Lacey, J. M. & Wilmore, D. W. Is Glutamine a Conditionally Essential Amino Acid? *Nutr. Rev.*  
974 **48**, 297–309 (1990).
- 975 77. Wen, Z. *et al.* Time-resolved online analysis of the gas- and particulate-phase of cigarette smoke  
976 generated by a heated tobacco product using vacuum ultraviolet photoionization mass spectrometry.  
977 *Talanta* **238**, 123062 (2022).
- 978 78. Benson, M. D. *et al.* Protein-metabolite association studies identify novel proteomic  
979 determinants of metabolite levels in human plasma. *Cell Metab.* **35**, 1646-1660.e3 (2023).
- 980 79. Van Dijk, G. The Role of Leptin in the Regulation of Energy Balance and Adiposity. *J.*  
981 *Neuroendocrinol.* **13**, 913–921 (2001).


- 982 80. de Castro, M. A., Baltar, V. T., Marchioni, D. M. L. & Fisberg, R. M. Sex differences in serum  
983 leptin and its relation to markers of cardiometabolic risk in middle-aged adults: Evidence from a  
984 population-based study. *Nutrition* **31**, 491–497 (2015).
- 985 81. Fluhr, L. *et al.* Gut microbiota modulates weight gain in mice after discontinued smoke  
986 exposure. *Nature* **600**, 713–719 (2021).
- 987 82. Lewis, C. M. *et al.* Genome scan meta-analysis of schizophrenia and bipolar disorder, Part II:  
988 schizophrenia. *Am. J. Hum. Genet.* **73**, 34–48 (2003).
- 989 83. Litwack, E. D., Babey, R., Buser, R., Gesemann, M. & O’Leary, D. D. M. Identification and  
990 characterization of two novel brain-derived immunoglobulin superfamily members with a unique  
991 structural organization. *Mol. Cell. Neurosci.* **25**, 263–274 (2004).
- 992 84. Takeuchi, A. & O’Leary, D. D. M. Radial Migration of Superficial Layer Cortical Neurons  
993 Controlled by Novel Ig Cell Adhesion Molecule MDGA1. *J. Neurosci.* **26**, 4460–4464 (2006).
- 994 85. Dócs, K. *et al.* The Ratio of 2-AG to Its Isomer 1-AG as an Intrinsic Fine Tuning Mechanism  
995 of CB1 Receptor Activation. *Front. Cell. Neurosci.* **11**, (2017).
- 996 86. Viveros, M. P., Marco, E. M. & File, S. E. Endocannabinoid system and stress and anxiety  
997 responses. *Pharmacol. Biochem. Behav.* **81**, 331–342 (2005).
- 998 87. Kersten, S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma  
999 lipid metabolism. *J. Lipid Res.* **62**, 100150 (2021).
- 1000 88. Kumar, A. A. *et al.* Plasma leptin level mirrors metabolome alterations in young adults.  
1001 *Metabolomics Off. J. Metabolomic Soc.* **16**, 87 (2020).
- 1002 89. Lawler, K. *et al.* Leptin-Mediated Changes in the Human Metabolome. *J. Clin. Endocrinol.*  
1003 *Metab.* **105**, 2541–2552 (2020).
- 1004 90. Alberti, K. G. M., Zimmet, P. & Shaw, J. The metabolic syndrome—a new worldwide definition.  
1005 *The Lancet* **366**, 1059–1062 (2005).
- 1006 91. Stelmach-Mardas, M. *et al.* Seasonality of food groups and total energy intake: a systematic  
1007 review and meta-analysis. *Eur. J. Clin. Nutr.* **70**, 700–708 (2016).

- 1008 92. van Ooijen, A. M. J., van Marken Lichtenbelt, W. D., van Steenhoven, A. A. & Westerterp, K.  
1009 R. Seasonal changes in metabolic and temperature responses to cold air in humans. *Physiol. Behav.*  
1010 **82**, 545–553 (2004).
- 1011 93. Dopico, X. C. *et al.* Widespread seasonal gene expression reveals annual differences in human  
1012 immunity and physiology. *Nat. Commun.* **6**, 7000 (2015).
- 1013 94. Wucher, V., Sodaei, R., Amador, R., Irimia, M. & Guigó, R. Day-night and seasonal variation  
1014 of human gene expression across tissues. *PLoS Biol.* **21**, e3001986 (2023).
- 1015 95. Suhre, K. *et al.* Human metabolic individuality in biomedical and pharmaceutical research.  
1016 *Nature* **477**, 54–60 (2011).
- 1017



1018 **Figures**

1019 **Fig. 1**



1020

1021 **Fig. 1 Longitudinal multi-omics profiling and co-expression analysis of human plasma**  
1022 **metabolites in 101 healthy individuals.**


1023 **a** Overview of the study design for the S3WP project, detailing the longitudinal data collection strategy  
1024 over six visits in two years (created with biorender.com). This included whole-genome sequencing,



1025 proteomics, metabolomics, lipidomics, clinical measurements, and lifestyle questionnaires from 101  
 1026 individuals. A total of 527 identified metabolites were categorized into 9 major classes. **b** UMAP  
 1027 clustering of the 527 metabolites showing their co-expression patterns, color-coded by their classes and  
 1028 grouped by co-expression clusters. **c** Sankey plot showing the distribution of metabolic classes across  
 1029 the clusters. **d** Bar plot showing the functional enrichment results of the metabolite clusters using  
 1030 Fisher's exact test.

1031

1032 **Fig. 2**




1033

1034 **Fig. 2 Inter- and intra-individual variability of plasma metabolites and seasonal influences**

1035 **a** The inter-individual and intra-individual variations of plasma metabolite levels, calculated as the  
 1036 coefficient of variation (CV) for each metabolite within each visit and across all participants, color-  
 1037 coded by metabolite classes. **b** Seasonal variation analysis of plasma metabolites using amplitude  
 1038 analysis, color-coded by metabolic classes. Y-axis showing the adjusted  $p$ -values with multiple test  
 1039 corrections using Benjamini and Hochberg method. **c** Heatmap showing the scaled levels of 121  
 1040 metabolites with significant seasonal variations across 12 months. **d-g** Plasma metabolite levels  
 1041 throughout the year for metabolites in Cluster M1-M4. **h** Pathway enrichment analysis of metabolites  
 1042 within each seasonal cluster. Significantly enriched pathways were defined with adjusted  $P$ -values <  
 1043 0.05 (Fisher's exact test with multiple test corrections using using Benjamini and Hochberg method). **i**,  
 1044 Vitamin D concentration levels across 12 months during the study period. **j**, Succinylcarnitine levels  
 1045 over 12 months as an example of metabolites in Cluster M3. Each line represents an individual; red  
 1046 lines indicate females and blue lines indicate males. Regression lines are added using trigonometric  
 1047 functions.


1048 **Fig. 3**



1049  
 1050 **Fig. 3 Influence of clinical measurements and lifestyle factors on metabolite levels.**

1051 **a** Canonical correspondence analysis (CCA) showing correlations between plasma metabolite levels,  
1052 clinical measurements and lifestyle variables. The upper and left bar plots show the estimated linear  
1053 regression coefficients for clinical and lifestyle variables with respect to CCA1 and CCA2. **b, d** Volcano  
1054 plots showing the impacts of sex (**b**) and BMI (**d**) on plasma metabolite levels (Kenward-Roger  
1055 approximation with Benjamini and Hochberg correction). **c** Concentration of gamma-glutamylleucine  
1056 across four study visits, shown as an example of a sex-associated metabolite. Each line represents an  
1057 individual; red lines indicate females and blue lines indicate males. **e** Scatter plot showing the  
1058 correlation between glutamic acid concentration and BMI, color-coded by BMI.

1059 **Fig. 4**




1060

1061 **Fig. 4 Genome-wide association analysis of the genetic regulation of the plasma metabolites.**

1062 **a** Manhattan plot showing the identified mQTLs in the study. Significant loci are annotated based on  
 1063 the closest gene, with colors indicating the class of the corresponding metabolite. **b** Chord diagram of  
 1064 loci shared ( $r^2 > 0.2$ ) among metabolites in GWAS study. Line thickness is proportionate to the  
 1065  $-\log_{10}(P)$ . **c** Manhattan plot of butyrylcarnitine showing the genome locations of all associated mQTLs.

1066 **d** Boxplot showing the association between plasma levels of butyrylcarnitine and the genotype of  
 1067 rs34673751, color-coded by the genotype of rs34673751. **e** Plasma levels of butyrylcarnitine across  
 1068 study visits; each individual is represented by a line; color-coded by the genotype of rs34673751. **f-g**  
 1069 Western blot showing increased butyrylcarnitine levels in the ACADS know-down 293T cell lines  
 1070 compared to the control group. **h** Manhattan plot for 4-androsten-3alpha,17alpha-diol monosulfate (2),  
 1071 showing the associated genetic loci. **i** Boxplot showing the association between plasma levels of 4-  
 1072 androsten-3alpha,17alpha-diol monosulfate (2) and the genotype of rs45446698. **j** Plasma levels of  
 1073 butyrylcarnitine across study visits; each individual is represented by a line; color-coded by the  
 1074 genotype of rs34673751.

1075 **Fig. 5**



1076  
 1077 **Fig. 5** Influence of genetic, clinical and lifestyle factors on plasma metabolite level variability.  
 1078 **a** Overview of influence of genetic, clinical and lifestyle factors on the plasma metabolite level  
 1079 variability. **b** Barplot showing the variance explanation fraction for each component across all 22






1085 **Fig. 6 Characterization of protein-metabolite network**

1086 **a** Network presenting the top 200 significant protein-metabolite pairs identified by the linear mixed  
1087 model (LMM) (FDR-adjusted  $P < 0.05$ ). Solid circles represent proteins in the inner ring, color-coded  
1088 by protein annotation. Squares represent metabolites in the outer ring, color-coded by different  
1089 metabolite-related influence factors. Pairs of related proteins and metabolites are connected by dashed  
1090 lines (indicating correlations supported by LMM results) and solid lines (indicating correlations  
1091 supported by both the LMM and Mendelian randomization (MR) analysis). Green lines indicate positive  
1092 correlations between proteins and metabolites in the LMM, while red lines indicate negative  
1093 correlations. **b** Scatter plot showing the correlation between aceturic acid concentration and LEP, color-  
1094 coded by sex. **c** Scatter plot showing the correlation between 1-Arachidonoylglycerol (1-AG)  
1095 concentration and MDGA1, color-coded by different genotypes of rs9349050. **d** Manhattan plot for  
1096 MDGA1 protein, showing the associated genetic variants with plasma levels of MDGA1. One of the  
1097 most significant SNP (rs9349050) was used as an instrumental variable in the MR analysis. **e** UMAP  
1098 clustering of the protein-metabolite profiles of the analyzed samples, color-coded by individual with  
1099 lines connecting the visits for each individual. **f, g** Bar plots showing the variance explanation fraction  
1100 of different genetic, clinical and lifestyle factors, calculated from linear mixed modeling, for UMAP1  
1101 (**f**) and UMAP2 (**g**). **h, i** Distribution of betweenness score of proteins (**h**) and metabolites (**i**) in three  
1102 tiers. **j, k** Dot plots highlighting the Tier 1 proteins (**j**) and metabolites (**k**)

1103 **Fig. 7**

1104





1105

1106 **Fig. 7 Predictive models for metabolic risk assessment**

1107 **a** Measurements of classical metabolic risk indicators, including HDL, BMI, SBP, TG and Gluc,  
 1108 compared between high risk and low risk groups. **b** Measurements of ALAT, GGT, urate, TNT and  
 1109 WBC for the high risk and low risk groups. **c** Area under the curve (AUC) of prediction models based  
 1110 on six different combinations of plasma proteins and metabolites: i) all proteins and metabolites; ii) tier

1111 1 proteins and metabolites; iii) all proteins; iv) tier 1 proteins; v) all metabolites; vi) tier 1 metabolites.  
1112 The AUC values were calculated by performing random sampling 100 times to account for variability.  
1113 **d** Average receiver operating characteristic (ROC) curves for the predictive models for the six  
1114 combination of plasma proteins and metabolites for predicting metabolic risk levels. **e, f** Linear model  
1115 coefficients obtained using Tier 1 proteins (**e**) and metabolites (**f**) as independent variables and a dummy  
1116 variable to indicate if the sample belonged to the high risk or low risk group. **g** Tier 1 proteins' profiles  
1117 of healthy individuals, compared with obesity, T2D, gout or hyperthyroidism in the UK Biobank. **h**  
1118 Average ROC curves obtained using Tier 1 proteins to predict individuals with either obesity, type 2  
1119 diabetes (T2D), gout, hyperthyroidism in the UK Biobank database. **i** Alluvial plot showing the risk  
1120 level of individual samples across visits. The y-axis represents the individuals involved in the study,  
1121 with colors indicating different risk levels. **j** BMI levels of the individual W0010 during the study visits.  
1122 **k** Changes in Tier 1 proteins over time in individual W0010 who lost a significant amount of weight  
1123 (15.4kg) between visit 3 and visit 4. **l** Average ROC curve of predictive models using Tier 1 proteins to  
1124 predict future obesity in the UK Biobank. The 95% confidence intervals (CI) of ROC curves were  
1125 plotted in **d, h, k** Red; High risk group, blue; Low risk group. High density lipoprotein, HDL; body  
1126 mass index, BMI; systolic blood pressure, SBP; triglycerides, TG; fasting glucose, Gluc; alanine  
1127 aminotransferase, ALAT; gamma glutamyltransferase, GGT, troponin T, TNT; white blood cells count,  
1128 WBC.

1129

## 1130 **Additional file 1**

1131 Supplementary Methods and Figures. Additional methods on experimental validation and figures S1-  
1132 S6.

1133 **Fig. S1** Co-expression clustering of 527 analyzed metabolites.

1134 **Fig. S2** Seasonal variation analysis of plasma metabolites and proteins.

1135 **Fig. S3** Mendelian randomization protein-metabolite network.

1136 **Fig. S4** Associations between Tier 1 proteins and metabolic diseases.

1137 **Fig. S5** Association between Tier 1 proteins and obesity.

1138 **Fig. S6** Prediction of future obesity in the UK Biobank.

1139 **Additional file 2**

1140 Table S1-S15.

1141 **Table S1.** Complete list of analyzed metabolites, proteins, and clinical parameters.

1142 **Table S2.** Classification and co-expression patterns of 527 analyzed metabolites.

1143 **Table S3.** Functional enrichment analysis of metabolite co-expression clusters.

1144 **Table S4.** Inter- and intra-individual variations of 527 analyzed metabolites.

1145 **Table S5.** Plasma metabolites with significant seasonal variation.

1146 **Table S6.** Temporal co-expression patterns of seasonal associated metabolites

1147 **Table S7.** Pathway enrichment analysis of metabolite co-expression clusters.

1148 **Table S8.** Temporal co-expression patterns of seasonally associated proteins.

1149 **Table S9.** Sex-associated plasma metabolites.

1150 **Table S10.** BMI-associated plasma metabolites.

1151 **Table S11.** Summary of identified independent mQTLs

1152 **Table S12.** Meta-analysis of identified independent mQTLs.

1153 **Table S13.** Contributions of genetics, lifestyle, and clinical factors to the variability of plasma  
1154 metabolites.

1155 **Table S14.** Comprehensive mixed-effect modeling analysis of protein-metabolite associations.

1156 **Table S15.** Summary of one-sample mendelian randomization analysis.